Human papillomavirus type 16 E6 variants in France and risk of viral persistence.
Fiche publication
Date publication
janvier 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CLAVEL Christine, Dr DALSTEIN Véronique
Tous les auteurs :
Cornet I, Gheit T, Clifford GM, Combes JD, Dalstein V, Franceschi S, Tommasino M, Clavel C
Lien Pubmed
Résumé
BACKGROUND: Only a small portion of HPV 16 infections persist and can lead to cervical intraepithelial lesions and cancer. Factors that favour HPV persistence versus clearance are still poorly understood, but several studies have suggested that HPV intra-type variants may influence persistence and clinical outcome. The aim of this study was to assess the possible association between HPV 16 variants and the risk for viral persistence in the general population of France. METHODS: One hundred and forty two women infected with HPV 16 with normal cytology, without previous treatment for cervical lesions, and with a valid second follow-up visit 4 to 16 months later, were selected from patients participating in routine cervical cancer screening in the Reims HPV Primary Screening Cohort Study. HPV intra-type variants were determined by sequencing the HPV 16 E6 open reading frame, and were compared for viral persistence at the second visit using odds ratios (OR) to estimate relative risk. RESULTS: Although no statistically significant differences in risk for persistence were observed by the HPV 16 variant lineage, European variants containing the polymorphism 350 T (EUR-350 T) appeared to persist more often than those containing 350 G (EUR-350 G) (OR = 1.6, 95% CI = 0.8-3.4). CONCLUSIONS: No strong differences were observed in the risk of viral persistence for the HPV 16 variants that predominate in France.
Référence
Infect Agent Cancer. 2013 Jan 23;8(1):4